Patent application number | Description | Published |
20100247517 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to the use of modulators of the kinase activity of Mnk1 and/or Mnk2 the diagnosis, alleviation, treatment and/or prevention of a tauopathy. Particularly, the present invention relates to the use of a modulator of Mnk1 and/or Mnk2 kinase for the diagnosis, alleviation, treatment and/or prevention of Alzheimer's disease. Preferably, the compounds are condensed pyrimidines. | 09-30-2010 |
20110003741 | NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE - The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability. | 01-06-2011 |
20110212102 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. | 09-01-2011 |
20110212103 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to novel thienopyrimidine compounds of general formula | 09-01-2011 |
20110217311 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to novel thienopyrimidine compounds of general formula | 09-08-2011 |
20110277045 | METHODS FOR INCREASING BETA CELL MASS COMPRISING ADMINISTERING A RA770 POLYPEPTIDE - The present invention discloses polynucleotides which identify and encode DP119, DP444, DP810, DP685, WE474, DP160, RA977, or RA770 as well as novel functions for these proteins of the inventions. The invention provides for compositions for disorders associated with the expression of the proteins of the invention, such as for the treatment, alleviation and/or prevention of pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), and related disorders, and other disease and disorders. | 11-10-2011 |
20120128686 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. | 05-24-2012 |
20130065914 | HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to novel thienopyhmidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. | 03-14-2013 |
20130231283 | NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE - The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability. | 09-05-2013 |